Racura Oncology opens South Korean trial for RC220
- Racura Oncology activated its first South Korean clinical site at Ewha Womans University Seoul Hospital for its RC220 trial.
- Following the announcement, the Racura Oncology share price was up at $2.23.
- The expansion aims to accelerate patient enrolment across four planned hospital sites in South Korea.
Racura Oncology (ASX:RAC) activated its first South Korean clinical trial site at Ewha Womans University Seoul Hospital for its CPACS Phase 1 trial of RC220.
The site activation follows earlier trial delays caused by required protocol modifications submitted to South Korean regulatory bodies.
"Activating the CPACS trial sites in Korea is an important milestone for Racura," said Racura Oncology CEO/MD Dr Daniel Tillett.
The company plans to activate three additional South Korean sites, including Severance Hospital on 4 September and Samsung Medical Centre on 8 September.
The company stated that opening these specialised local sites is expected to accelerate trial progress.
Following the announcement, the Racura Oncology share price was up at $2.23.
Racura Oncology focuses on developing targeted cancer therapies to improve clinical outcomes for patients with advanced solid tumours.
The company continues to advance its clinical trial pipeline across international sites to evaluate the cardioprotection and anticancer synergy of RC220.
Frequently asked questions
More from Australia
Resurgent inflation pressures test key Australian consumer shares
The digital cart rush redefining Australian retail profit pools
Trans-Tasman insurers battle contract churn while defending profit margins
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access
